In Leishmania infantum–endemic countries, controlling infection within dogs, the domestic reservoir, is critical to public health. There is a need for safe vaccines that prevent canine progression with disease and transmission to others. Protective vaccination against Leishmania requires mounting a strong, inflammatory, Type 1 response. Three commercially available canine vaccines on the global veterinary market use saponin or inflammatory antigen components (Letifend) as a strong pro-inflammatory adjuvant. There is very little information detailing safety of saponin as an adjuvant in field trials. Safety analyses for the use of vaccine as an immunotherapeutic in asymptomatically infected animals are completely lacking. Leishmania infantum, the causative agent of canine leishmaniasis, is enzootic within U.S. hunting hounds. We assessed the safety of LeishTec® after use in dogs from two different clinical states: 1) without clinical signs and tested negative on polymerase chain reaction and serology or 2) without clinical signs and positive for at least one Leishmania diagnostic test. Vaccine safety was assessed after all three vaccinations to quantify the number and severity of adverse events. Vaccinated animals had an adverse event rate of 3.09%, whereas placebo animals had 0.68%. Receiving vaccine was correlated with the occurrence of mild, site-specific, reactions. Occurrence of severe adverse events was not associated with having received vaccine. Infected, asymptomatic animals did not have a higher rate of adverse events. Use of vaccination is, therefore, likely to be safe in infected, asymptomatic animals.
Read the full article in The American of Tropical Medicine and Hygiene.
More from CNAS
CommentaryThe Pentagon must act now to address vulnerability in its enterprise
The Defense Department cannot wait for another stress test before addressing fragility in its enterprise; it must learn and adapt now....
By Tara Murphy Dougherty & Billy Fabian
CommentaryStorm Clouds Ahead: Musings About the 2022 Defense Budget
One hopes Washington won’t lose another year as its competitors continue to chip away at America’s conventional overmatch....
By Robert O. Work
CommentaryAll About Eve: What Virtual Forever Wars Can Teach us About the Future of Combat
The defense world could learn a lot from the gaming world. In some cases, it already has....
By Tom Shugart
CommentaryWant an Agile Pentagon? Don’t Go Chasing ‘Waterfalls’
Clinging to familiar, outdated processes will provide little comfort when China surpasses the United States as the world’s foremost military power....
By Chris Dougherty